GLDI | ZSB | GLDI / ZSB | |
Gain YTD | 16.591 | 11.315 | 147% |
Net Assets | 69.5M | 1.42M | 4,887% |
Total Expense Ratio | N/A | 0.59 | - |
Turnover | N/A | 38.00 | - |
Yield | 7.81 | 2.70 | 289% |
Fund Existence | 13 years | 3 years | - |
GLDI | ZSB | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago67% |
Stochastic ODDS (%) | 2 days ago78% | 2 days ago64% |
Momentum ODDS (%) | 2 days ago83% | N/A |
MACD ODDS (%) | 2 days ago67% | 2 days ago74% |
TrendWeek ODDS (%) | 2 days ago79% | 2 days ago72% |
TrendMonth ODDS (%) | 2 days ago77% | 2 days ago76% |
Advances ODDS (%) | 2 days ago78% | 30 days ago70% |
Declines ODDS (%) | 10 days ago67% | N/A |
BollingerBands ODDS (%) | 2 days ago84% | N/A |
Aroon ODDS (%) | 2 days ago80% | 2 days ago76% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ENHNX | 10.36 | 0.01 | +0.10% |
Cullen Enhanced Equity Income I | |||
PFISX | 12.00 | N/A | N/A |
Principal International Small Company R6 | |||
VVOSX | 22.74 | N/A | N/A |
Invesco Value Opportunities R6 | |||
FBTTX | 26.30 | N/A | N/A |
Fidelity Advisor Biotechnology M | |||
SROAX | 13.30 | -0.10 | -0.75% |
Calamos Antetokounmpo Sustainable Eqs A |
A.I.dvisor tells us that ZSB and SQM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZSB and SQM's prices will move in lockstep.